MWVC
TGTX icon

Morgens Waterfall Vintiadis & Co’s TG Therapeutics TGTX Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,000
Closed -$1.74M – 40
2021
Q1 		$1.74M Hold
36,000
– – 0.96% 29
2020
Q4 		$1.87M Buy
+36,000
New +$1.22M 1.01% 25

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's TGTX Position: Q2 2021 in Review

Morgens Waterfall Vintiadis & Co sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 36,000 shares — an estimated $1.74M sold.

Morgens Waterfall Vintiadis & Co first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.87M in Q4 2020. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Morgens Waterfall Vintiadis & Co reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 36,000 TG Therapeutics shares in Q2 2021, an estimated $1.74M.
  • Morgens Waterfall Vintiadis & Co first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
  • Morgens Waterfall Vintiadis & Co's TG Therapeutics position peaked at $1.87M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2021, filed 16 Aug 2021.